Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

You might develop blurry vision or other trouble seeing. This could be a sign of age-related macular degeneration (AMD). Wet AMD is the advanced form of the disease. It happens when new blood ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

An announcement from Opthea Limited ( (AU:OPT) ) is now available.

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

A new eye drop therapy offers a non-invasive alternative for treating dry age-related macular degeneration. Massively ...

Neovascular AMD is an advanced form of the condition, also known as “exudative AMD" or “wet macular degeneration.” The wet form is less common than the dry form of AMD, occurring in roughly ...

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced central ...